Literature DB >> 9466317

Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization.

J S Boyle1, C Koniaras, A M Lew.   

Abstract

We examined the role of the cellular localization of antigen on the immune response after DNA immunization of mice with three forms of ovalbumin (OVA). DNA encoding OVA which was secreted (sOVA) generated 10- to 100-fold higher IgG responses with 50-and 100-fold higher levels of IgG1 than the cytoplasmic (cOVA) or membrane bound (mOVA) forms. An IgG2a predominance was seen only in cOVA and mOVA immunized mice. Although the antibody response was CD4+ T cell dependent, the differences in the antibody response could not be compensated for by provision of excess CD4+ T cell help in TCR transgenic mice. Together with our hapten-carrier studies, this would indicate that membrane or intracellular localization limits the availability of antigen for B cell priming which affects the magnitude and form of the antibody response. Surprisingly, stronger cytotoxic T lymphocyte (CTL) responses were generated for sOVA or mOVA than for cOVA via intramuscular (i.m.) injection. Since a cytoplasmic antigen should have best access to the canonical class I pathway for antigen presentation, our results indicate that priming of CTL responses after i.m. DNA immunization is probably by cross-presentation of antigen by non-transfected professional antigen-presenting cells. In contrast, intradermal immunization with cOVA produced optimal CTL responses but, as with mOVA, suboptimal antibody responses. This, together with our ex vivo RT-PCR analysis showing similar mRNA levels from all three constructs 7 days post-immunization, argues against the differential CTL response for i.m. injection to be due to dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9466317     DOI: 10.1093/intimm/9.12.1897

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  44 in total

Review 1.  Strategies for improving responses to DNA vaccines.

Authors:  J S Boyle; I G Barr; A M Lew
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B- and T-cell responses in outbred animals.

Authors:  Waithaka Mwangi; Wendy C Brown; Gary A Splitter; Christopher J Davies; Chris J Howard; Jayne C Hope; Yoko Aida; Yan Zhuang; Beverly J Hunter; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

5.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

8.  Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Authors:  Jin-Won Youn; Su-Hyung Park; Jae Ho Cho; Young Chul Sung
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

10.  Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.

Authors:  Z Zhang; C Kuscu; S Ghazizadeh
Journal:  Gene Ther       Date:  2009-05-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.